- Case report
- Open Access
- Open Peer Review
Corticosteroid dose increase is a risk factor for nonalcoholic fatty liver disease and contralateral osteonecrosis of the femoral head: a case report
BMC Musculoskeletal Disordersvolume 20, Article number: 88 (2019)
The incidence of bilateral corticosteroid-induced osteonecrosis of the femoral head (ONFH) is high. Although the precise mechanism of corticosteroid-induced ONFH development is unclear, hepatic enzyme abnormalities such as low activity of hepatic cytochrome P450 3A could be one cause. Herein, we report the case of a patient who developed ONFH in the contralateral hip after the dose of corticosteroids for idiopathic thrombocytopenic purpura was increased. Liver biopsy was done to rule out autoimmune hepatitis.
A 32-year-old woman had been treated with continuous corticosteroids of up to 10 mg/day for Sjögren’s syndrome for 25 years and corticosteroid-induced ONFH in the left side. At age 33, idiopathic thrombocytopenia developed, which was treated by increasing the corticosteroid dose (40 mg/day). Two months later, liver enzyme level began to increase slightly and continued to increase. A year after corticosteroid dose increase, contralateral ONFH developed, and a liver biopsy demonstrated nonalcoholic fatty liver disease (NAFLD).
The current case indicates that corticosteroid dose increase is a potential risk factor for NAFLD and contralateral ONFH. Therefore, it would be useful and important for to screen and monitor patients with hepatic enzyme abnormality for ONFH occurrence.
Non-traumatic osteonecrosis of the femoral head (ONFH) is believed to be a multifactorial disease, with high-dose corticosteroid therapy for inflammatory diseases and alcohol abuse considered major risk factors [1, 2]. ONFH can be bilateral in up to 60% of cases at initial diagnosis . In contrast, patients with unilateral ONFH rarely develop a subsequent osteonecrotic lesion in the contralateral femoral head. To our knowledge, there have been three cases of new corticosteroid-induced ONFH developing in the contralateral femoral head [4,5,6].
The underlying mechanism in corticosteroid-induced ONFH is still unclear. A previous clinical study reported that the activity of hepatic cytochrome P450 3A, which metabolizes corticosteroids, was related to corticosteroid-induced ONFH . Additionally, several animal studies have reported abnormal hepatic metabolism to be involved in the development of corticosteroid-induced ONFH [8,9,10]. Therefore, abnormal hepatic metabolism might be associated with the occurrence of corticosteroid-induced ONFH. However, the three case reports on contralateral ONFH did not clearly observe associations with abnormal hepatic metabolism. Little attention has been paid to the associations between development of new corticosteroid-induced ONFH lesions and hepatic abnormality observed in liver biopsy.
Herein, we report the case of a patient who developed new ONFH in the contralateral hip after the dose of corticosteroids for an idiopathic thrombocytopenic purpura (ITP) was increased and who underwent liver biopsy to rule out autoimmune hepatitis.
A 32-year-old woman (height, 150.8 cm; weight, 50.7 kg; body mass index, 22.3 kg/m2) had been treated with continuous corticosteroids of up to 10 mg/day for Sjögren’s syndrome since age 8 (Fig. 1). She had no history of alcohol abuse. At age 32, she had groin pain without any antecedent trigger activities. Plain radiography at the same month after onset did not show obvious abnormalities (Fig. 2a). T1-weighted magnetic resonance imaging (MRI) at 3 months after the onset of pain clearly showed a low-intensity band within the left femoral head (Fig. 2b). We diagnosed her with ONFH (type C-2, stage 1) based on the Japanese Investigation Committee (JIC) classification [11, 12]. There was no obvious abnormality in the right femoral head.
At age 33, ITP developed, which was treated by corticosteroid dose increase (40 mg/day) followed by oral corticosteroid therapy (30 mg/day) for 1 year. After the ITP improved, continuous corticosteroid treatment was administered for Sjögren’s syndrome and ITP using a similar regimen as before (10 mg/day). At age 34, 1 year after the corticosteroid dose was increased, T1-weighted MRI demonstrated a low-intensity band within the right femoral head (Fig. 3). Then, she was diagnosed with right ONFH (type C-1, stage 1).
Serum aspartate aminotransferase and alanine aminotransferase levels were elevated after ITP onset and corticosteroid dose increase, and these levels continued to increase over 1 year (Fig. 1). To rule out autoimmune hepatitis associated with ITP, she underwent a liver biopsy 1 year after the corticosteroid dose was increased. Subsequently, she was diagnosed with nonalcoholic fatty liver disease (NAFLD) induced by corticosteroid treatment (Fig. 4). After the corticosteroid dose was tapered to 10 mg/day, serum liver function improved.
Written informed consent for publication of the case was obtained from the patient.
Discussion and Conclusions
We present a case of bilateral corticosteroid-induced ONFH in which the timing of development of ONFH in each of the femoral heads and corticosteroid-induced NAFLD differed. On the left side (initial occurrence side), the timing of ONFH occurrence and whether it was corticosteroid-induced ONFH were difficult to determine because a higher dose of glucocorticoid (maximum dose; 10 mg/day) was not administered until the initial occurrence. On the contrary, after the corticosteroid dose was increased from 5 to 10 mg/day to 40 mg/day, ONFH developed on the contralateral side, which did not show evidence of osteonecrosis on the first MRI, indicating the difference in the timing of osteonecrosis development. This finding that increasing corticosteroid dose from 5 to 10 mg/day to 40 mg/day might have induced contralateral ONFH is consistent with a previous report . Koo et al. reported that ONFH occurred in patients who received corticosteroid up to 16 months after initiation of corticosteroid therapy , and Piyakunmala et al. reported the high incidence rate and high extension area of asymptomatic osteonecrosis of the contralateral femoral head of the hip in high-risk patients in a cross-sectional study . Therefore, the increase in corticosteroid dose in this case might have reached a new threshold, which triggers ONFH occurrence. Because it was not fully understood whether glucocorticoid dose increase could be a risk factor for contralateral ONFH occurrence, future observational studies are needed.
Consistent with the other three cases of new corticosteroid-induced ONFH development in the contralateral femoral head [4,5,6], in this case, the occurrence of contralateral ONFH was also seen in a relatively short time after the corticosteroid dose was increased. Additionally, considering the elevation of liver enzymes following an increase in corticosteroid dose as well as the pathological findings of the liver biopsy (corticosteroid-induced NAFLD), abnormal hepatic metabolism induced by corticosteroid treatment might play an important role in ONFH occurrence. However, this is contrary to another clinical report in which a high risk of ONFH in systemic lupus erythematosus (SLE) patients showed no immediate increase in hepatic enzyme under steroid therapy . Okazaki et al. reported that the absence of any response to steroid therapy in the liver may be implicated in the pathogenesis of ONFH . However, the current case is different from Okazaki’s study in terms of the duration of corticosteroid intake and the lack of SLE.
Several animal studies focused on the correlation between cytochrome P450 3A activity and the incidence of osteonecrosis  . Additionally, clinical reports showed that low hepatic cytochrome P450 3A activity is a risk factor for corticosteroid-induced osteonecrosis  . Unfortunately, our patient was not examined then. Therefore, whether abnormal hepatic metabolism could directly play an important role in ONFH occurrence remains unclear. However, recent reports showed the association between reduced level of cytochrome P450 3A activity and expression in NAFLD  as well as between corticosteroid use and NAFLD . Given this finding, abnormal hepatic metabolism and hepatic steatosis after corticosteroid dose increase or high-dose corticosteroid initiation should be monitored. Additionally, future observational studies on corticosteroid dose increase should focus on cytochrome P450 3A activity and address the correlation of ONFH occurrence and liver enzyme abnormalities.
The current case indicates that corticosteroid dose increase is a potential risk factor for NAFLD and contralateral ONFH. Therefore, it would be useful and important to screen and monitor patients with hepatic enzyme abnormality for ONFH occurrence.
idiopathic thrombocytopenic purpura
nonalcoholic fatty liver disease
osteonecrosis of the femoral head
systemic lupus erythematosus
Fukushima W, Fujioka M, Kubo T, Tamakoshi A, Nagai M, Hirota Y. Nationwide epidemiologic survey of idiopathic osteonecrosis of the femoral head. Clin Orthop Relat Res. 2010;468:2715–24.
Oinuma K, Harada Y, Nawata Y, Takabayashi K, Abe I, Kamikawa K, et al. Osteonecrosis in patients with systemic lupus erythematosus develops very early after starting high dose corticosteroid treatment. Ann Rheum Dis. 2001;60:1145–8.
Min BW, Song KS, Cho CH, Lee SM, Lee KJ. Untreated asymptomatic hips in patients with osteonecrosis of the femoral head. Clin Orthop Relat Res. 2008;466:1087–92.
Sonoda K, Yamamoto T, Motomura G, Yamaguchi R, Karasuyama K, Iwamoto Y. Contralateral osteonecrosis of the femoral head newly developed after increasing the dose of corticosteroids. J Orthop Sci. 2015;20:772–5.
Sonoda K, Yamamoto T, Motomura G, Hamai S, Karasuyama K, Kubo Y, et al. Bilateral corticosteroid-induced osteonecrosis of the femoral head detected at a 6-week interval. Springerplus. 2015;4:662.
Zhao FC, Cang DW, Shen XF, Guo KJ. Does the necrosis develop simultaneously in patients with bilateral hips necrosis? A case report. Orthop Surg. 2015;7:77–80.
Kaneshiro Y, Oda Y, Iwakiri K, Masada T, Iwaki H, Hirota Y, et al. Low hepatic cytochrome P450 3A activity is a risk for corticosteroid-induced osteonecrosis. Clin Pharmacol Ther. 2006;80:396–402.
Masada T, Iwakiri K, Oda Y, Kaneshiro Y, Iwaki H, Ohashi H, et al. Increased hepatic cytochrome P4503A activity decreases the risk of developing steroid-induced osteonecrosis in a rabbit model. J Orthop Res. 2008;26:91–5.
Okazaki S, Nishitani Y, Nagoya S, Kaya M, Yamashita T, Matsumoto H. Femoral head osteonecrosis can be caused by disruption of the systemic immune response via the toll-like receptor 4 signalling pathway. Rheumatology (Oxford). 2009;48:227–32.
Okazaki S, Nagoya S, Yamamoto M, Tateda K, Takahashi H, Yamashita T, et al. High risk of osteonecrosis of the femoral head in autoimmune disease patients showing no immediate increase in hepatic enzyme under steroid therapy. Rheumatol Int. 2013;33:51–5.
Sugano N, Atsumi T, Ohzono K, Kubo T, Hotokebuchi T, Takaoka K. The 2001 revised criteria for diagnosis, classification, and staging of idiopathic osteonecrosis of the femoral head. J Orthop Sci. 2002;7:601–5.
Asano T, Takahashi D, Shimizu T, Irie T, Arai R, Terkawi MA, et al. A mathematical model for predicting postoperative leg shortening after curved intertrochanteric varus osteotomy for osteonecrosis of the femoral head. PLoS One. 2018;13:e0208818.
Koo KH, Kim R, Kim YS, Ahn IO, Cho SH, Song HR, et al. Risk period for developing osteonecrosis of the femoral head in patients on steroid treatment. Clin Rheumatol. 2002;21:299–303.
Piyakunmala K, Sangkomkamhang T, Chareonchonvanitch K. Is magnetic resonance imaging necessary for normal plain radiography evaluation of contralateral non-traumatic asymptomatic femoral head in high osteonecrosis risk patient. J Med Assoc Thail. 2009;92(Suppl 6):S147–51.
Ikemura S, Yamamoto T, Motomura G, Yamaguchi R, Zhao G, Iwasaki K, et al. Cytochrome P4503A activity affects the gender difference in the development of steroid-induced osteonecrosis in rabbits. Int J Exp Pathol. 2014;95:147–52.
Nafziger AN, Bertino JS Jr. Low hepatic cytochrome P450 3A activity is a risk for corticosteroid-induced osteonecrosis. Clin Pharmacol Ther. 2007;82:379 author reply 380.
Woolsey SJ, Mansell SE, Kim RB, Tirona RG, Beaton MD. CYP3A activity and expression in nonalcoholic fatty liver disease. Drug Metab Dispos. 2015;43:1484–90.
Woods CP, Hazlehurst JM, Tomlinson JW. Glucocorticoids and non-alcoholic fatty liver disease. J Steroid Biochem Mol Biol. 2015;154:94–103.
No funding was obtained for this study.
Availability of data and materials
All data concerning the case are presented in the manuscript.
Ethics approval and consent to participate
Consent for publication
Written informed consent was obtained from the patient for the publication of this case report, along with any accompanying images. A copy of the written consent is available for review by the Editor of this journal.
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.